ALB and anemia: In addition, the common AEs in camrelizumab monotherapy or camrelizumab plus albumin-bound paclitaxel regimen are reactive cutaneous capillary endothelial proliferation (RCCEP) (79.26% and 80.33%, respectively), followed by hematologic toxicity, including neutrophil count decreased (69.67% and 65.19%, respectively), white blood cell count decreased (68.03% and 53.33%, respectively), anemia (62.30%% and 62.22%, respectively), and platelet count decreased (48.36% and 39.26%, respectively).